[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350991-105":59,"doc-detail-350991-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","diagnostic-efficiency-of-age-adjusted-psad-for-prostate-cancer-and-clinically-significant-prostate-cancer-construction-and-nomogram-validation","Diagnostic Efficiency of Age-Adjusted PSAD for Prostate Cancer and Clinically Significant Prostate Cancer - Construction and Nomogram Validation","","Prostate-Specific Antigen (PSA) screening for prostate cancer has limited specificity, producing false positives and unnecessary biopsies. This study evaluates Age-Adjusted Prostate-Specific Antigen Density (A-PSAD) as a biomarker to improve detection of prostate cancer (PCa) and clinically significant prostate cancer (csPCa). Among 663 biopsy patients (2020–2024), A-PSAD and PSAD were compared, and lasso-selected variables supported a nomogram model. A-PSAD showed superior AUCs and sensitivity/specificity balance.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/diagnostic-efficiency-of-age-adjusted-psad-for-prostate-cancer-and-clinically-significant-prostate-cancer-construction-and-nomogram-validation/350991/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/diagnostic-efficiency-of-age-adjusted-psad-for-prostate-cancer-and-clinically-significant-prostate-cancer-construction-and-nomogram-validation/350991.png","ImageObject",300,407,{"name":92,"@type":93},"Aria","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What problem does the study address in PSA-based prostate cancer screening?","Question",{"text":113,"@type":114},"PSA has low specificity in the “gray zone,” which can cause false-positive results and lead to unnecessary biopsies and overdiagnosis.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was A-PSAD developed and what variables were used?",{"text":118,"@type":114},"The study proposes Age-Adjusted PSAD (A-PSAD) and compares it with PSAD. Lasso regression selected key variables such as age, diabetes history, FPSA, prostate volume, and A-PSAD to build a nomogram.",{"name":120,"@type":111,"acceptedAnswer":121},"What were the main findings about diagnostic performance?",{"text":122,"@type":114},"A-PSAD outperformed PSAD for both PCa and csPCa screening, with higher AUC values and a decision curve showing high clinical benefit across most risk thresholds. Adding PI-RADS improved performance in high-risk patients without significant difference from the base model.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},350991,1790126548,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":105,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","Journal of Clinical Laboratory Analysis   \n RESEARCH ARTICLE  OPEN ACCESS   \nDiagnostic Efficiency of Age-Adjusted PSAD for Prostate Cancer and Clinically Significant Prostate Cancer:  \nConstruction and Nomogram Validation  \nZiyang Liu1  | Jiahao Shan1  | Qiang Zhang2 | Yu Gao2 | Zhiyong Lv2 | Lianghong Ma2,3,4 | Hongbin Shi2  \n1The First Clinical Medical College, Ningxia Medical University, Yinchuan, China | 2Department of Urology, General Hospital of, Ningxia Medical University, Yinchuan, China | 3Institute of Medical Sciences, Ningxia Human Sperm Bank, General Hospital of, Ningxia Medical University, Yinchuan,  \nChina | 4Key Laboratory of Fertility Preservation and Maintenance of Ministry of Education, Ningxia Medical University, Yinchuan, China Correspondence: Lianghong Ma ([mmm1770@163.com](mmm1770@163.com)) | Hongbin Shi ([shb0525@163.com](shb0525@163.com))  \nReceived: 17 June 2025 | Revised: 21 October 2025 | Accepted: 16 November 2025  \nKeywords: clinically significant prostate cancer | diagnosis | lasso regression | prostate cancer | prostate-specific antigen density  \nABSTRACT  \nBackground: Prostate-Specific Antigen (PSA) is widely used for Prostate Cancer (PCa) screening, but its low specificity often leads to false-positive results and unnecessary biopsies. To address this issue, we introduced Age-Adjusted Prostate-Specific Antigen Density (A-PSAD) as a potential biomarker to improve screening accuracy for PCa and Clinically Significant Prostate Cancer (csPCa) .  \nMethods: In this study, 663 patients who underwent prostate biopsy between 2020 and 2024 were included. The diagnostic performance ofA-PSAD, PSAD, and other biomarkers was compared. Key variables, including age, diabetes history, FPSA, prostate volume, and A-PSAD, were selected using Lasso regression to develop a nomogram prediction model (Nomo1). Additionally, the PI-RADS score was incorporated into a second model (Nomo2) .  \nResults: A-PSAD outperformed PSAD in PCa and csPCa screening. For PCa, A-PSAD had a higher AUC (0.753 vs. 0.732) with 71.86% sensitivity and 70.69% specificity, compared to PSAD's 74.87% and 63.15% . For csPCa, A-PSAD's AUC was 0.731 versus 0.708, with sensitivities of 76.27% and 57.61% . The nomogram model, based on Lasso-selected variables, achieved AUCs of 0.796 and 0.812 in the training and validation sets, with C-indices of 0.7870 and 0.7935, indicating good predictive performance. Decision curve analysis showed high clinical benefit across most risk thresholds. Incorporating PI-RADS, the Nomo2 model improved diagnostic performance in high-risk patients (AUC 0.8202) without significant difference from Nomo1 (AUC 0.8198, p >0.05) .  \nConclusion: A-PSAD offers a better balance between sensitivity and specificity compared to PSAD, reducing false positives and unnecessary biopsies, and presents a promising tool for personalized PCa screening.  \n1 | Introduction  \nProstate cancer (PCa) is one of the most common malignancies among men worldwide [1]. With the global population aging, the incidence of PCa continues to rise, particularly among elderly  \nmen, where the mortality rate is significantly higher [2, 3] . Since PCa often presents without obvious symptoms in its early stages, early screening is crucial for reducing mortality and improving cure rates [4, 5]. Currently, Prostate-Specific Antigen (PSA) testing is the standard method for PCa screening; however, when  \n\n| Jiahao Shan and Ziyang Liu contributed equally to this work. |\n| --- |\n| This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.\u003Cbr>© 2026 The Author(s). Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC. |\n\nJournal of Clinical Laboratory Analysis, 2026; 40:e70135 1 of 11  \n[https://doi.org/10.1002/jcla.70135](https:/","cbCaisQ0HRXYRLAs","https://ap.wps.com/l/cbCaisQ0HRXYRLAs","pdf",2346188,"English","# Introduction\n## Diagnostic challenges of PSA and PSAD\n# Methods\n## Patient cohort and biopsy selection\n## Lasso regression and nomogram construction\n## PI-RADS integration\n# Results\n## Comparative diagnostic performance\n## Training/validation model discrimination\n# Conclusion","[{\"question\":\"What problem does the study address in PSA-based prostate cancer screening?\",\"answer\":\"PSA has low specificity in the “gray zone,” which can cause false-positive results and lead to unnecessary biopsies and overdiagnosis.\"},{\"question\":\"How was A-PSAD developed and what variables were used?\",\"answer\":\"The study proposes Age-Adjusted PSAD (A-PSAD) and compares it with PSAD. Lasso regression selected key variables such as age, diabetes history, FPSA, prostate volume, and A-PSAD to build a nomogram.\"},{\"question\":\"What were the main findings about diagnostic performance?\",\"answer\":\"A-PSAD outperformed PSAD for both PCa and csPCa screening, with higher AUC values and a decision curve showing high clinical benefit across most risk thresholds. Adding PI-RADS improved performance in high-risk patients without significant difference from the base model.\"}]","Diagnostic Efficiency of Age-Adjusted PSAD for Prostate Cancer and Clinically Significant Prostate Cancer - Construction and Nomogram Validation | PDF",1790092215,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f6ff342bbd21daa44a9cfd47441e4dbd.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/05f0fd1bf5e2340d3c119fffdb74ff5e.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5ad08c816ccc690e35042915f66c326c.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d50edf0c1712e04048eb6ef7e756c661.webp",980,1287]